Let's look at why this news could be a game-changer for Eli Lilly and its stock.

LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor ... oral drug for obesity. The candidate also met the key secondary endpoint in the ACHIEVE-1 study ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate ... not enough to significantly impact the stock. Pfizer's stock traded mostly flat in ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

The jump in share price propelled the stock into ... Image source: Getty Images. What sets orforglipron apart from most other GLP-1 drugs on the market is that it's an oral drug.

but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the first of several phase 3 drug trials. The jump in share price propelled the stock ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

Image Source ... developing its oral obesity pill, amycretin, in a mid-stage study. Amycretin is a dual receptor agonist that targets two key gut hormones, GLP-1 and amylin.

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the ...